Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Endoxifen

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44363   clinical trials with a EudraCT protocol, of which   7387   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    13 result(s) found for: Endoxifen. Displaying page 1 of 1.
    EudraCT Number: 2020-004828-42 Sponsor Protocol Number: ATOS-016R Start Date*: 2021-08-30
    Sponsor Name:Atossa Therapeutics Inc.
    Full Title: A Phase 2, Randomized, Double-blinded, Placebo - controlled, Dose Response Study of Oral (Z)-endoxifen in Premenopausal Women with Measurable Breast Density
    Medical condition: The mammographic density reduction in healthy women
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-004854-27 Sponsor Protocol Number: PROTAM Start Date*: 2020-02-27
    Sponsor Name:Erasmus MC Cancer Institute
    Full Title: The influence of UGT inhibition on endoxifen exposure in cancer patients treated with tamoxifen: A proof of concept study. “The PROTAM study”
    Medical condition: Hormone positive breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2022-002426-28 Sponsor Protocol Number: 81896-PREDICTAM Start Date*: 2022-11-14
    Sponsor Name:Erasmus MC Cancer Institute
    Full Title: Predicting an accurate tamoxifen dose: a feasibility study in patients with hormone positive breast cancer
    Medical condition: Hormone positive breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-000573-72 Sponsor Protocol Number: ATOS-010 Start Date*: 2018-04-21
    Sponsor Name:Atossa Genetics Inc
    Full Title: Karma CREME-1: A double-blind, placebo-controlled, three-armed, pilot study of the effects, safety and tolerability of topical endoxifen in women within the Karma Cohort
    Medical condition: The mammographic density reduction in healthy women.
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2016-000418-31 Sponsor Protocol Number: IKP275 Start Date*: 2019-04-01
    Sponsor Name:Robert Bosch Gesellschaft für medizinische Forschung mbH
    Full Title: GENOTYPE AND PHENOTYPE GUIDED SUPPLEMENTATION OF TAMOXIFEN STANDARD THERAPY WITH ENDOXIFEN IN BREAST CANCER PATIENTS.
    Medical condition: Patients with ductal carcinoma in situ (DCIS) or early stage breast cancer.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006199 Breast cancer stage I PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006200 Breast cancer stage II PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006201 Breast cancer stage III PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-002910-37 Sponsor Protocol Number: TEA Start Date*: 2019-10-07
    Sponsor Name:Erasmus MC
    Full Title: Study on the pharmacokinetic interaction between green tea and tamoxifen in patients with breast cancer. “the TEA study”
    Medical condition: Breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-005124-24 Sponsor Protocol Number: 6378707817 Start Date*: 2018-01-31
    Sponsor Name:Erasmus MC Cancer Institute
    Full Title: Therapeutic Drug Monitoring guided tamoxifen dosing: a feasibility study in patients with hormone positive breast cancer
    Medical condition: Hormone positive breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-004008-71 Sponsor Protocol Number: ELDORADO Start Date*: 2017-01-19
    Sponsor Name:Erasmus MC Cancer Institute
    Full Title: The effect of curcumin and piperine on the pharmacokinetics of tamoxifen in patients with estrogen receptor positive breast cancer ‘the ELDORADO study’
    Medical condition: Estrogen receptor positive breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2011-002727-18 Sponsor Protocol Number: Lisette-2 Start Date*: 2011-10-24
    Sponsor Name:
    Full Title: The effects of switching antidepressants on endoxifen exposure
    Medical condition: Breast cancer
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070577 Oestrogen receptor positive breast cancer LLT
    Population Age: Adults Gender: Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-002942-40 Sponsor Protocol Number: HPC 01/2007 Start Date*: 2007-09-12
    Sponsor Name:Fundación de la Comunidad Valenciana Hospital Provincial de Castellón
    Full Title: EXPLORATORY STUDY OF THE EFFECT OF THREE DIFFERENT LEVELS OF DOSES OF TAMOXIFEN (20, 40 Y 60 MG/DAY) OVER THE PLASMATIC CONCENTRATION OF THE MAIN ACTIVE TAMOXIFEN METABOLITE (ENDOXIFEN) IN PATIENTS...
    Medical condition: WOMEN WITH HORMONE-DEPENDENT RESECTED PRIMARY BREAST CANCER, WITHOUT EVIDENCE OF METASTATIC DISEASE AND CARRIERS OF A CYP2D6 GENOTYPE “POOR METABOLIZER”. Cáncer de mama operado y sin diseminación ...
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-000288-18 Sponsor Protocol Number: I3Y-MC-JPCG Start Date*: 2016-07-21
    Sponsor Name:Lilly S.A.
    Full Title: A Randomized, Open-Label, Phase 2 Study of Abemaciclib plus Tamoxifen or Abemaciclib Alone, in Women with Previously Treated Hormone Receptor-Positive, HER2-Negative, Metastatic Breast Cancer
    Medical condition: Breast cancer
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed) AT (Completed) BE (Completed) DE (Completed) CZ (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2021-004536-28 Sponsor Protocol Number: 1 Start Date*: 2021-11-15
    Sponsor Name:Uppsala University, Department of Women's and Children´s Health
    Full Title: Vaginal administration of selective estrogen receptor modulator (Tamoxifen) treatment to improve sexual function for women with breast cancer. A randomized, double-blinded, placebo controlled longi...
    Medical condition: Most troublesome vulvovaginal atrophy symptom
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-000641-44 Sponsor Protocol Number: TailorDose-II Start Date*: 2017-04-28
    Sponsor Name:Karolinska intitutet
    Full Title: TailorDose®-II: Therapeutic dose monitoring of commonly used cytostatic drugs/regimes indicated for breast cancer
    Medical condition: Newly diagnosed pre- or post-operative breast cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006188 Breast cancer female NOS LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: SE (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Nov 05 12:20:40 CET 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA